Skip to main content
. 2012 Dec;167(8):1620–1628. doi: 10.1111/j.1476-5381.2012.02098.x

Figure 1.

Figure 1

URB937 is peripherally restricted in female mice. (A) FAAH activity in liver and brain 1 h after injection of URB937 (0.03–100 mg·kg−1, s.c.) in female C57BL6 mice. (B) Brain FAAH activity after systemic administration of vehicle or a supra-maximal dose of URB937 (25 mg·kg−1, s.c.); URB937 was administered alone or in combination with the Abcg2 inhibitor Ko-143 (Ko, 10 mg ·kg−1, i.p.), the SULT1 inhibitor DCNP (30 mg·kg−1, i.p.) or both. Effects of vehicle (open columns) or URB937 (1 mg·kg−1, i.p., solid columns) on (C) anandamide and (D) PEA levels in liver, kidney, forebrain, spinal cord and ovary of female C57BL6 mice 2 h after administration. Results are expressed as mean ± SEM; n= 3–7; **P < 0.01 and ***P < 0.001 versus vehicle; ###P < 0.001 versus URB937 alone; &&&P < 0.001 versus URB937 plus Ko-143 and URB937 plus DCNP.